Z

Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267

Watchlist Manager
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Watchlist
Price: 8.29 CNY -0.96%
Market Cap: 9.7B CNY
Have any thoughts about
Zhejiang Hisun Pharmaceutical Co Ltd?
Write Note

Zhejiang Hisun Pharmaceutical Co Ltd
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Hisun Pharmaceutical Co Ltd
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Total Current Liabilities
ÂĄ7B
CAGR 3-Years
-7%
CAGR 5-Years
-9%
CAGR 10-Years
1%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Liabilities
ÂĄ6.9B
CAGR 3-Years
37%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Current Liabilities
ÂĄ2.5B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
26%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Liabilities
ÂĄ4.8B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Liabilities
ÂĄ13.8B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Liabilities
ÂĄ1.1B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Hisun Pharmaceutical Co Ltd
Glance View

Market Cap
10B CNY
Industry
Pharmaceuticals

Zhejiang Hisun Pharmaceutical Co., Ltd. unfolds its story in the competitive arena of China's booming pharmaceutical industry. Founded in 1956, Hisun has gradually matured from a regional player into a recognized name in global generic and specialty drug manufacturing. The company's core strength lies in its integration across the pharmaceutical supply chain, which allows it to produce active pharmaceutical ingredients (APIs) while also scaling up to final dosage forms. Hisun capitalizes on its robust research and development capabilities, investing heavily in innovation to expand its diverse pharmaceutical product portfolio. Through strategic partnerships and collaborative ventures, such as alliances with leading biotech firms, Hisun not only enhances its technological footprint but fortifies its international presence, poised to address the increasing global demand for affordable healthcare solutions. In the sprawling marketplace, Hisun’s financial model is driven by its synergistic blend of producing generic medications and investing in biopharmaceuticals. The firm enjoys a lucrative revenue stream by tapping into the cost-effective production of APIs, which are integral to numerous medications worldwide. Through vertically integrated operations, the company achieves economies of scale, facilitating competitive pricing. Hisun’s foray into more value-added, complex generics and biosimilars further diversifies its income channels, transforming challenges into opportunities amid stringent global regulatory landscapes. By navigating these complexities, Hisun strengthens its market position, leveraging a balance between solid internal growth and strategic global outreach, thus sustaining its journey within the dynamic panorama of the pharmaceutical sector.

Intrinsic Value
13.13 CNY
Undervaluation 37%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Hisun Pharmaceutical Co Ltd's Total Current Liabilities?
Total Current Liabilities
7B CNY

Based on the financial report for Sep 30, 2024, Zhejiang Hisun Pharmaceutical Co Ltd's Total Current Liabilities amounts to 7B CNY.

What is Zhejiang Hisun Pharmaceutical Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
1%

Over the last year, the Total Current Liabilities growth was 7%. The average annual Total Current Liabilities growth rates for Zhejiang Hisun Pharmaceutical Co Ltd have been -7% over the past three years , -9% over the past five years , and 1% over the past ten years .

Back to Top